WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Exelixis revenue was $2.17B for the trailing 12 months ending Dec 31, 2024, with 176.9% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $566.8M, up 5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EXEL annual revenue was $2.2B, with 18.5% growth year-over-year.

EXEL past revenue growth

How has EXEL's revenue growth performed historically?

Company
18.49%
Industry
497.69%
Market
20.68%
EXEL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EXEL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EXEL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EXEL revenue history

Current Revenue
$2.2B
Current Earnings
$521.3M
Current Profit Margin
24%

Be the first to know when EXEL announces revenue.

EXEL Revenue History By Year

EXEL Yearly RevenueEXEL RevenueEXEL ChangeEXEL Revenue Growth
2024-12-31$2.17B$338.49M+18.49%
2023-12-31$1.83B$219.15M+13.60%
2022-12-31$1.61B$176.09M+12.27%
2021-12-31$1.43B$447.43M+45.31%
2020-12-31$987.54M$19.76M+2.04%
2019-12-31$967.78M$113.95M+13.35%
2018-12-31$853.83M$401.35M+88.70%
2017-12-31$452.48M$261.02M+136.34%
2016-12-31$191.45M$154.28M+415.05%
2015-12-31$37.17M$12.06M+48.03%
2014-12-31$25.11M-$6.23M-19.87%
2013-12-31$31.34M-$16.11M-33.96%
2012-12-31$47.45M-$242.19M-83.62%
2011-12-31$289.64M$104.59M+56.52%
2010-12-31$185.05M$33.29M+21.93%
2009-12-31$151.76M$33.90M+28.76%
2008-12-31$117.86M$4.39M+3.87%
2007-12-31$113.47M$14.80M+15.00%
2006-12-31$98.67M$22.71M+29.90%
2005-12-31$75.96M$23.10M+43.71%
2004-12-31$52.86M$1.32M+2.56%
2003-12-31$51.54M$7.22M+16.29%
2002-12-31$44.32M$3.32M+8.09%
2001-12-31$41.01M$16.25M+65.62%
2000-12-31$24.76M$14.25M+135.58%
1999-12-31$10.51M$8.24M+362.59%
1998-12-31$2.27MN/AN/A
1997-12-31$0.00N/AN/A

1 of 2

Exelixis Revenue FAQ

What was EXEL's revenue last quarter?

On Invalid Date, Exelixis (NASDAQ: EXEL) reported Q4 2024 revenue of $566.76 million up 18.16% year over year. In the same quarter last year, Exelixis's revenue was $479.65 million.

What was Exelixis's revenue in 2024?

Exelixis's annual revenue for the twelve months ending Dec 31, 2024 was $2.17 billion, a 18.49% increase year over year.

How much does Exelixis make in a day?

Based on Exelixis annual revenue for the past five years, EXEL makes an average of $4,401,358.36 per day.

What was Exelixis's annual revenue growth in the past year?

As of Q2 2025, Exelixis's revenue has grown 18.49% year over year. This is 479.2 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Exelixis's revenue in the past year totaled $2.17 billion.

How much does Exelixis make in a year?

Exelixis's revenue by year for the past five years is:
  • Exelixis's revenue for the twelve months ending Dec 31, 2024 was $2.17 billion, a 18.49% increase year over year.
  • Exelixis's annual revenue for Dec 31, 2023 was $1.83 billion, a 13.6% increase from 2022.
  • Exelixis's annual revenue for 2022 was $1.61 billion, a 12.27% increase from 2021.
  • Exelixis's annual revenue for 2021 was $1.43 billion, a 45.31% increase from 2020.
  • Exelixis's annual revenue for 2020 was $987.54 million, a 2.04% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.